Silo Pharma is a developmental stage biopharmaceutical company focused on developing novel formulations of traditional and psychedelic therapeutics to address underserved conditions. Their pipeline includes innovative programs for PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis. Silo Pharma collaborates with leading universities and laboratories and anticipates a streamlined 505(b)(2) route for trials to lower costs and expedite the approval process.
We're tracking Silo Pharma's market expansion
How Silo Pharma's international expansion compares to its competitors
Silo PharmaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Silo PharmaYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Silo Pharma announced European Patent Office approval for a licensed patent covering preventative PTSD therapy targeting the 5-HT4 pathway, expanding its intellectual property portfolio for stress-induced fear and depressive behavior prevention.
Be the first to find verified contacts at Silo Pharma
Quick answers about Silo Pharma's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
